CLRB
Cellectar Biosciences, Inc.NASDAQHealthcare$2.55+6.27%ClosedMarket Cap: $8.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.16
P/S
0.00
EV/EBITDA
0.18
DCF Value
$4.38
FCF Yield
-267.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-248.9%
ROA
-145.5%
ROIC
-222.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-5.7M | $-5.3M | $-1.25 | — |
| FY 2025 | $0.00 | -Infinity% | $-23.0M | $-21.8M | $-8.35 | — |
| Q3 2025 | $0.00 | -Infinity% | $-4.9M | $-4.4M | $-1.41 | — |
| Q2 2025 | $0.00 | NaN% | $-6.0M | $-5.4M | $-3.39 | — |
| Q1 2025 | $0.00 | NaN% | $-6.4M | $-6.6M | $-4.30 | — |
| Q4 2024 | $0.00 | NaN% | $-12.7M | $-2.4M | $-1.68 | — |
| FY 2024 | $0.00 | NaN% | $-51.8M | $-44.6M | $-41.89 | — |
| Q3 2024 | $0.00 | NaN% | $-13.3M | $-14.7M | $-11.18 | — |
| Q2 2024 | $0.00 | NaN% | $-13.7M | $-919.4K | $-5.43 | — |
| Q1 2024 | $0.00 | NaN% | $-12.0M | $-26.6M | $-27.24 | — |
| Q4 2023 | $0.00 | NaN% | $-12.5M | $-7.9M | $-12.17 | — |
| FY 2023 | $0.00 | NaN% | $-39.0M | $-42.8M | $-104.99 | — |